Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.
- CAS Registry Number
- 502-85-2
- Molecular formula
- C4H7NaO3
- Molecular weight
- 126.09 g/mol
- Drug class
- Gamma-hydroxybutyrate (GHB/oxybate)central nervous system depressant
- Mechanism of action
- Acts through GHB and GABA-B receptor pathways. The precise mechanism by which sodium oxybate improves symptoms of narcolepsy is not fully understood; it affects sleep architecture and may consolidate nocturnal sleep, with downstream effects on cataplexy and excessive daytime sleepiness.
- Indications / reported uses
- Treatment of cataplexy in narcolepsy
- Treatment of excessive daytime sleepiness in narcolepsy, including in paediatric patients where the formulation and local authorisation permit
Identification source: PubChem record (CID 23663870). The linked PubChem record is provided for identity reference. Confirm the exact salt, hydrate, isomer, mixture, or product form against authoritative source documentation when defining the assessment scope.